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Background: Recently approved in the United States, percutaneous pulmonary valve implantation (PPVI) is an alternative to surgical conduit 
revision in select patients with congenital right ventricular outflow tract obstruction and pulmonary insufficiency. The objective of this study was to 
evaluate and model the cost-effectiveness of the percutaneous option compared to standard surgical approach.
Methods: We examined the last 17 patients who underwent PPVI at our institution and compared them with our 17 most-recent surgically placed 
valves. Economic data comparing the two options was obtained from the actual procedural and in-hospital charges including associated costs to 
the institution. Societal costs due to lost wages were gathered from the U.S. Department of Labor to determine the broader socio-economic impact 
of each procedure. Sensitivity analysis evaluated the effects of varying reintervention rates to determine a 10-year cost-effectiveness model for each 
option.
Results: Groups were similar with respect to age, number of pre-procedure catheterizations and symptoms. Median total hospital and procedural 
charges incurred by the patient were significantly higher for the surgical valve compared to PPVI ($126,406 ± $38,772 vs. $80,328 ± $17,387, p 
< 0.001). Median total societal charges were also higher for the surgical valve ($129,519 ± $39,021 vs. $80,939 ± $17,334, p <0.001) owing to 
an average wage loss of $3,113 for patients who had surgery, contrasted to $611 who underwent PPVI. This was due to shorter recovery times and 
shorter length of stay (1.0 ± 0 vs. 5.7 ± 2.2, p <0.001) for PPVI. Using previously published data, the average reintervention rate for surgically placed 
pulmonary valves was found to be approximately 2% per year. Sensitivity analysis determined that PPVI would need to have a 10-year failure rate of 
approximately 57% to lose its cost-effectiveness advantage.
Conclusions: Based on recent data, PPVI holds a significant cost advantage over the traditional surgical approach, fewer hospital days, and incurs 
noticeably less patient wage loss. Further, it would need to have a very high failure rate at 10 years to become less cost-effective. 
